Sr. Director, Head of GU Oncology Lifecycle Management

Natera is a global leader in cell-free DNA testing focused on changing the management of disease in reproductive health, oncology, and organ transplantation.  Signatera is a personalized, tumor-informed test for molecular residual disease (MRD) assessment and surveillance monitoring in patients previously diagnosed with cancer.  Signatera is covered by Medicare for colorectal cancer, muscle invasive bladder cancer, high-risk breast cancer, ovarian cancer, lung cancer, and immunotherapy response monitoring for any solid tumor. 

As the Head of GU Oncology Lifecycle Management, you will shape the vision and strategy for Natera’s oncology product portfolio in GU cancers. Your leadership will drive a cohesive, cross-functional approach—partnering with medical, sales, business development, and other key teams—to position our products effectively and address critical unmet needs in cancer care.

Reporting directly to the VP of Oncology Lifecycle Management, you will own the GU disease area strategy, and make high-impact decisions to maximize the clinical and commercial success of our oncology solutions. 

PRIMARY RESPONSIBILITIES:

• Own the lifecycle planning and success of GU cancers, collaborating with cross-functional teams to develop and execute a strategic plan that drives usage, awareness, and advocacy across key stakeholders worldwide.
• Expand Signatera access across GU tumors – prioritize key indications, own evidence roadmaps, close evidence gaps and submit for coverage
• Establish tumor-specific goals to be owned by the lifecycle team and across functions.
• Serve as a critica